Business Description
Syndax Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US87164F1057
Description
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 353.26 | |||||
| Equity-to-Asset | 0.9 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -20.2 | |||||
| 3-Year EPS without NRI Growth Rate | -16.8 | |||||
| 3-Year FCF Growth Rate | -9.8 | |||||
| 3-Year Book Growth Rate | 7.4 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 36.92 | |||||
| 9-Day RSI | 37.28 | |||||
| 14-Day RSI | 40.56 | |||||
| 6-1 Month Momentum % | 98.24 | |||||
| 12-1 Month Momentum % | 5.02 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 10 | |||||
| Quick Ratio | 10 | |||||
| Cash Ratio | 9.94 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -21 | |||||
| Shareholder Yield % | 0.53 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -47.23 | |||||
| ROA % | -43.61 | |||||
| ROIC % | -824.67 | |||||
| ROC (Joel Greenblatt) % | -14480.2 | |||||
| ROCE % | -47.1 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 3.18 | |||||
| Price-to-Tangible-Book | 3.18 | |||||
| EV-to-EBIT | -5.77 | |||||
| EV-to-EBITDA | -5.77 | |||||
| EV-to-Forward-Revenue | 33.35 | |||||
| EV-to-FCF | -7.51 | |||||
| Price-to-Net-Current-Asset-Value | 3.38 | |||||
| Price-to-Net-Cash | 3.4 | |||||
| Earnings Yield (Greenblatt) % | -17.33 | |||||
| FCF Yield % | -9.09 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers